Cleveland BioLabs [CBLI -Nasdaq]: la BIO sponsorizzata dai russi....

[alumnum]

Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of products for cancer treatment, and protection of normal tissues from radiation and other acute stresses. Its lead Protectan, CBLB502, is a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and intestine. The company also offers Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation; and Curaxins, which are small molecules that induce apoptosis in a range of human tumor cells and sensitize tumor cells to the apoptosis-inducing effects of other anti-cancer treatments. Its products in pre-clinical stage comprise Revercom, a chemotherapy adjuvant; Mobilan for immunotherapy; Arkil, an inhibitor of androgen receptor; Antimycon, an inhibitor of myc oncogene; and Xenomycins, which are small molecules that target facilitates chromatin transcription. The company has strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children’s Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

Cleveland BioLabs' Anti-Radiation Drug Makes It A Tempting Speculative Buy - Seeking Alpha